Table 2 Demographics and drug use histories of pilesorting study participants (N = 28)
Variable | N (%) |
|---|---|
Age (median, interquartile range [IQR]) | 42 (34, 53) |
Ethnicity | |
Latino or Hispanic | 1 (3.6) |
Not Latino or Hispanic | 27 (96.4) |
Race | |
White | 15 (53.6) |
Black/African American | 12 (42.9) |
Othera | 1 (3.6) |
Gender | |
Male | 20 (71.4) |
Female | 7 (25.0) |
Transgender Female | 1 (3.6) |
Education | |
Less than High School graduate | 4 (14.3) |
Grade 12 or GED | 15 (53.6) |
1–3 years of college | 9 (32.1) |
College graduate | 0 (0) |
Main living situation in the past 30 days | |
My own home or apartment | 16 (57.1) |
Halfway/three-quarter house or other transitional house | 3 (10.7) |
A friend’s home | 3 (10.7) |
A shelter | 3 (10.7) |
On the street | 2 (7.1) |
Otherb | 2 (7.1) |
Age at first opioid use (median, IQR)c | 24 (16, 32) |
Drug(s) of choiced | |
Heroin/fentanyl | 20 (71.4) |
Cannabis | 9 (32.1) |
Powder cocaine | 8 (28.6) |
Alcohol | 7 (25.0) |
Crack cocaine | 6 (21.4) |
Prescription opioids | 3 (10.7) |
Benzodiazepines | 2 (7.1) |
Methamphetamine/amphetamine | 1 (3.6) |
PCP/Wet/Angel Dust | 1 (3.6) |
Synthetic cannabinoids (“K2”) | 1 (3.6) |
Buprenorphine/methadone | 1 (3.6) |
Ecstasy | 1 (3.6) |
Past 30-day used | |
Nicotine | 20 (71.4) |
Heroin/fentanyl | 13 (46.4) |
Cannabis | 13 (46.4) |
Alcohol | 9 (32.1) |
Crack cocaine | 9 (32.1) |
Powder cocaine | 7 (25.0) |
Benzodiazepines | 4 (14.3) |
Methamphetamine/amphetamine | 1 (3.6) |
Prescription opioids | 1 (3.6) |
PCP/Wet/Angel Dust | 1 (3.6) |
Synthetic cannabinoids (“K2”) | 1 (3.6) |
Ecstasy | 3 (10.7) |
Kratom | 1 (3.6) |
Program | |
Stephen Klein Wellness Center | 8 (28.6) |
Pathways to Housing PA | 13 (46.4) |
Hub of Hope | 7 (25.0) |
Number of days participant took MOUD in the past 7 days | |
1 | 1 (3.6) |
2 | 0 (0) |
3 | 2 (7.1) |
4 | 5 (17.9) |
5 | 4 (14.3) |
6 | 1 (3.6) |
7 | 15 (53.6) |
Previous substance use disorder treatment modalitiesd | |
Inpatient | 23 (82.1) |
Outpatient | 26 (92.9) |
Methadone | 16 (57.1) |
Naltrexone (Vivitrol) | 4 (14.3) |
Another buprenorphine program | 12 (42.9) |
AA/NA/other abstinence-based group | 19 (67.9) |
Individual therapy | 19 (67.9) |
Length of participation in this program | |
< 3 months | 3 (10.7) |
3–6 months | 6 (21.4) |
6 months - 1 year | 4 (14.3) |
1–2 years | 7 (25.0) |
2-3 years | 3 (10.7) |
> 3 years | 5 (17.9) |
Communication with Suboxone provider during COVID-19 | |
More than once a week | 3 (10.7) |
Once a week | 9 (32.1) |
3 times a month | 5 (17.9) |
2 times a month | 5 (17.9) |
Once a month or less | 6 (21.4) |